Friedreich's Ataxia Program News

Our team of Friedreich's ataxia experts provides comprehensive care, from initial diagnosis and testing through long-term disease management.

How we serve you

267-426-7538

FDA Approves First Drug for Friedreich’s Ataxia

Mar 1, 2023

The drug, omaveloxolone, is a once-a-day pill that will help improve neurological function and slow progression of the neurodegenerative disease.

Friedreich’s Ataxia Center of Excellence at CHOP Awarded $1.275 Million to Advance Medical Research

Dec 10, 2020

The Friedreich’s Ataxia Center of Excellence at CHOP was awarded $1.275 million by the Friedreich’s Ataxia Research Alliance, Hamilton and Finneran families and the CureFA Foundation

In Pursuit of Cure for a Rare Degenerative Disease

Nov 8, 2017

A rare degenerative disease strikes during childhood. A multimillion-dollar gift is fueling CHOP scientists’ search for a cure.

$3.25 Million Gift Creates Friedreich’s Ataxia Center of Excellence

Mar 6, 2014

Donations from Friedreich’s Ataxia Research Alliance and the Hamilton and Finneran Families helps launch Penn Medicine/CHOP Center to improve research and care for Friedreich's Ataxia, a rare, degenerative disease.

Find a research study

Innovation and your child

Find research studies

Friedreich's Ataxia Program News

FDA Approves First Drug for Friedreich’s Ataxia

Friedreich’s Ataxia Center of Excellence at CHOP Awarded $1.275 Million to Advance Medical Research

In Pursuit of Cure for a Rare Degenerative Disease

$3.25 Million Gift Creates Friedreich’s Ataxia Center of Excellence